Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 09, 2022

BUY
$0.16 - $100.0 $14,732 - $9.21 Million
92,075 Added 39.23%
326,808 $50,000
Q2 2022

Aug 11, 2022

SELL
$0.2 - $0.5 $7,466 - $18,665
-37,331 Reduced 13.72%
234,733 $97,000
Q1 2022

May 12, 2022

BUY
$0.41 - $0.63 $2,194 - $3,372
5,353 Added 2.01%
272,064 $150,000
Q4 2021

Feb 11, 2022

BUY
$0.57 - $1.29 $64,953 - $146,999
113,953 Added 74.6%
266,711 $155,000
Q3 2021

Nov 12, 2021

BUY
$1.11 - $1.7 $46,644 - $71,437
42,022 Added 37.95%
152,758 $188,000
Q2 2021

Aug 10, 2021

BUY
$1.46 - $2.25 $108,310 - $166,916
74,185 Added 202.96%
110,736 $187,000
Q1 2021

May 12, 2021

SELL
$1.77 - $2.93 $225,798 - $373,780
-127,570 Reduced 77.73%
36,551 $65,000
Q4 2020

Feb 10, 2021

BUY
$2.13 - $3.26 $169,379 - $259,238
79,521 Added 94.0%
164,121 $351,000
Q3 2020

Nov 12, 2020

BUY
$1.53 - $3.13 $56,429 - $115,440
36,882 Added 77.29%
84,600 $253,000
Q2 2020

Aug 13, 2020

BUY
$0.48 - $1.75 $22,904 - $83,506
47,718 New
47,718 $72,000
Q1 2020

May 13, 2020

SELL
$0.56 - $0.97 $8,454 - $14,644
-15,097 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$0.62 - $1.06 $620 - $1,060
1,000 Added 7.09%
15,097 $13,000
Q3 2019

Nov 12, 2019

BUY
$0.81 - $1.06 $5,331 - $6,976
6,582 Added 87.58%
14,097 $14,000
Q2 2019

Aug 09, 2019

SELL
$0.94 - $1.6 $2,545 - $4,332
-2,708 Reduced 26.49%
7,515 $8,000
Q1 2019

May 13, 2019

SELL
$0.51 - $1.88 $36,376 - $134,092
-71,326 Reduced 87.46%
10,223 $16,000
Q4 2018

Feb 06, 2019

BUY
$0.39 - $3.47 $18,777 - $167,073
48,148 Added 144.15%
81,549 $35,000
Q3 2018

Nov 08, 2018

BUY
$1.39 - $2.25 $12,451 - $20,155
8,958 Added 36.65%
33,401 $71,000
Q2 2018

Aug 14, 2018

BUY
$1.44 - $2.24 $35,197 - $54,752
24,443 New
24,443 $35,000
Q1 2018

May 11, 2018

SELL
$1.51 - $2.06 $7,155 - $9,762
-4,739 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$1.4 - $2.6 $6,634 - $12,321
4,739
4,739 $8,000

About TREVENA INC


  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $273M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.